儿童斑秃新型靶向药物治疗研究进展

doi:10.35541/cjd.20230660

Abstract

Abstract: 【Abstract】 In recent years, a variety of small-molecule targeted drugs and biological agents have shown promising efficacy and good safety for alopecia areata in clinical studies. Several targeted drugs have been approved for the treatment of moderate to severe pediatric alopecia areata in China and other countries. This review summarizes the recent progress in the application of these drugs for pediatric alopecia areata.

Key words: Alopecia areata, Biological agents, Child, JAK-STAT inhibitors, Treatment

Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata[J]. Chinese Journal of Dermatology,2024,e20230660. doi:10.35541/cjd.20230660

References ［30］

［1］	Bhardwaj P, Basu D, Podder I, et al. Clinico⁃epidemiological profile of childhood alopecia areata along with dermoscopic correlation: a cross⁃section, observational study［J/OL］. Indian Dermatol Online J, 2021,12（2）:250⁃257. doi: 10.4103/idoj.IDOJ_451_20.
［2］	Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2020,82（3）:675⁃682. doi: 10.1016/j.jaad.2019.08.032.
［3］	Peloquin L, Castelo⁃Soccio L. Alopecia areata: an update on treatment options for children［J］. Paediatr Drugs, 2017,19（5）:411⁃422. doi: 10.1007/s40272⁃017⁃0239⁃z.
［4］	Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（4）:1164⁃1166. doi: 10.1016/j.jaad.2018.12.041.
［5］	Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children［J］. J Am Acad Dermatol, 2019,80（2）:568⁃570. doi: 10.1016/j.jaad.2018.08.041.
［6］	Jerjen R, Meah N, Trindade de Carvalho L, et al. Treatment of alopecia areata in pre⁃adolescent children with oral tofacitinib: a retrospective study［J］. Pediatr Dermatol, 2021,38（1）:103⁃108. doi: 10.1111/pde.14422.
［7］	Huang J, Li T, Tan Z, et al. Effectiveness of tofacitinib in pre⁃adolescent alopecia areata: a retrospective case series and literature review［J］. Acta Derm Venereol, 2023,103:adv13418. doi: 10.2340/actadv.v103.13418.
［8］	刘元香, 梁源, 赵欣荣, 等. JAK抑制剂治疗儿童重症斑秃5例［J］. 中华皮肤科杂志, 2023,56（9）:849⁃852. doi: 10.35541/cjd. 20220317.
［9］	Dube V. Recovery of alopecia universalis with associated nail dystrophy treated with tofacitinib: a 6⁃year⁃old child's case report［J］. Int J Trichology, 2021,13（6）:32⁃33. doi: 10.4103/ijt.ijt_91_21.
［10］	Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis［J］. JAMA Dermatol, 2021,157（3）:352⁃353. doi: 10.1001/jamadermatol.2020.4555.
［11］	Asfour L, Bokhari L, Bhoyrul B, et al. Treatment of moderate⁃to⁃severe alopecia areata in pre⁃adolescent children with baricitinib［J］. Br J Dermatol, 2023,189（2）:248⁃250. doi: 10.1093/bjd/ljad118.
［12］	Rotaru S, Common M, Mahé E. Severe inflammatory tinea capitis in a child receiving baricitinib therapy for alopecia areata［J］. Ann Dermatol Venereol, 2023,150（2）:160⁃161. doi: 10.1016/j.annder.2023.02.001.
［13］	Fiocco Z, Kerl K, French LE, et al. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis［J］. Dermatol Ther, 2022,35（4）:e15351. doi: 10.1111/dth.15351.
［14］	Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（2）:566⁃568. doi: 10.1016/j.jaad.2018.08.040.
［15］	Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:850⁃856. doi: 10.1111/jdv.15489.
［16］	Ali NS, Tollefson MM, Lohse CM, et al. Incidence and comorbidities of pediatric alopecia areata: a retrospective matched cohort study using the Rochester Epidemiology Project［J］. J Am Acad Dermatol, 2022,87（2）:427⁃429. doi: 10.1016/j.jaad.2021.08.050.
［17］	Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221138452. doi: 10.1177/2050313X221138452.
［18］	Yu D, Ren Y. Upadacitinib for successful treatment of alopecia universalis in a child: a case report and literature review［J］. Acta Derm Venereol, 2023,103:adv5578. doi: 10.2340/actadv.v103.5578.
［19］	King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double⁃blind, multicentre, phase 2b⁃3 trial［J］. Lancet, 2023,401（10387）:1518⁃1529. doi: 10.1016/S0140⁃6736（23）00222⁃2.
［20］	Zhao J, Liu L. A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib［J］. JAAD Case Rep, 2022,22:99⁃100. doi: 10.1016/j.jdcr.2022.02.027.
［21］	Huang J, Liu O. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib［J］. J Cosmet Dermatol, 2024,23（1）:348⁃349. doi: 10.1111/jocd.15896.
［22］	Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.
［23］	Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo⁃controlled single⁃center pilot study of the safety and efficacy of apremilast in subjects with moderate⁃to⁃severe alopecia areata［J］. Arch Dermatol Res, 2019,311（1）:29⁃36. doi: 10.1007/s00403⁃018⁃1876⁃y.
［24］	Chhabra G, Verma P. Steroid⁃resistant alopecia totalis in a child successfully treated with oral apremilast and platelet⁃rich plasma therapy［J］. Dermatol Ther, 2019,32（6）:e13082. doi: 10.1111/dth.13082.
［25］	Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a janus effect［J］. Dermatol Ther, 2019,32（5）:e13023. doi: 10.1111/dth.13023.
［26］	Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata［J］. J Am Acad Dermatol, 2023,88（3）:651⁃653. doi: 10.1016/j.jaad.2019.06.010.
［27］	Cho SK, Craiglow BG. Dupilumab for the treatment of alopecia areata in children with atopic dermatitis［J］. JAAD Case Rep, 2021,16:82⁃85. doi: 10.1016/j.jdcr.2021.07.015.
［28］	McKenzie PL, Castelo⁃Soccio L. Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis［J］. J Am Acad Dermatol, 2021,84（6）:1691⁃1694. doi: 10.1016/j.jaad.2021.01.046.
［29］	Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata［J］. Pediatr Dermatol, 2019,36（1）:e44⁃e45. doi: 10.1111/pde.13699.
［30］	Ortolan LS, Kim SR, Crotts S, et al. IL⁃12/IL⁃23 neutralization is ineffective for alopecia areata in mice and humans［J］. J Allergy Clin Immunol, 2019,144（6）:1731⁃1734.e1. doi: 10.1016/j.jaci. 2019.08.014.

[1]	Huang Hejin, Li Xinya, He Ziqing, Xi Wenwen, Tang Yujun, Zhang Jianfei, Xiao Xia, Jiang Bin, Yang Feng. Postoperative complications in 3 000 patients with axillary osmidrosis after minimally invasive rotary cutting surgery: a retrospective study [J]. Chinese Journal of Dermatology, 2025, 0(5): 20230291-e0230291.
[2]	Xiao Xing, Wang Shan, Yang Huan, Shu Hong, Guo Yanping, Chen Jinping, Lu Yao, Li Qinfeng, Liang Yuan, Zhao Mutong, Luo Xiaoyan, Miao Limin, Xu Rui, Li Xuemei, Lai Sha, Li Jianhong, Luo Zhen, Yu Lu, Xing Lu, Wang Meitan, Li Xiaoli, Xu Haitao, Li Ping, Wang Hua, Ma Lin. Comparison of efficacy and safety of crisaborole ointment 2% versus pimecrolimus cream 1% in the treatment of mild to moderate atopic dermatitis in children: a multicenter, randomized, controlled clinical trial [J]. Chinese Journal of Dermatology, 2025, 58(5): 425-430.
[3]	Deng Wei, Jiang Lixiao, Su Wei, Yang Zhou, Liu Xiaoyan, Zhang Gaolei. Clinical analysis of 15 cases of Mycoplasma pneumoniae-induced rash and mucositis [J]. Chinese Journal of Dermatology, 2025, 58(5): 460-463.
[4]	The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404.
[5]	China Dermatologist Association, Treatment Group, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Diagnosis and treatment of bullous pemphigoid: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 405-415.
[6]	Bao Shijie, Han Mei, Zhou Xiaoyong. Analysis of factors influencing the efficacy of etanercept in the treatment of toxic epidermal necrolysis based on literature review [J]. Chinese Journal of Dermatology, 2025, 58(4): 352-355.
[7]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[8]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[9]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the diagnosis and treatment of paraneoplastic pemphigus in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 289-296.
[10]	Wang Caixia, Xu Fan, Shi Jing, Zhu Hailian, Lu Guiling, Wang Hongmei. Efficacy and safety of omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220929-e0220929.
[11]	Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240247-e20240247.
[12]	Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301.
[13]	Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of tea polyphenol antioxidant gel combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 0(2): 20240421-e20240421.
[14]	Guo Weinan, Wang Junxia, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Clinical efficacy of autologous adipose-derived stem cell gel grafting in the treatment of depressed acne scars [J]. Chinese Journal of Dermatology, 2025, 58(2): 167-169.
[15]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.

Novel targeted drugs for the treatment of pediatric alopecia areata

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［30］

Related Articles 15

Metrics

Comments

Recommended 10